Literature DB >> 34170209

Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf.

Xiaoting Hua1,2,3, Jintao He1,2,3, Jingfen Wang1,2,3, Linghong Zhang1,2,3, Linyue Zhang1,2,3, Qingye Xu1,2,3, Keren Shi1,2,3, Sebastian Leptihn1,4, Yue Shi5, Xiaoting Fu6,7, Pengfei Zhu6,7, Paul G Higgins8,9, Yunsong Yu1,2,3.   

Abstract

AbstractAcinetobacter baumannii is an important pathogen in hospital acquired infections. Although tigecycline currently remains a potent antibiotic for treating infections caused by multidrug resistant A. baumannii (MDRAB) strains, reports of tigecycline resistant isolates have substantially increased. The resistance mechanisms to tigecycline in A. baumannii are far more complicated and diverse than what has been described in the literature so far. Here, we characterize in vitro-selected MDRAB strains obtained by increasing concentrations of tigecycline. We have identified mutations in adeS, rrf and rpoB that result in reduced susceptibility to tigecycline. Using in situ complementation experiments, we confirm that mutations in rrf, rpoB, and two types of mutations in adeS correlate with tigecycline resistance. By Western blot and polysome profile analysis, we demonstrate that the rrf mutation results in decreased expression of RRF, which affects the process of ribosome recycling ultimately leading to increased tigecycline tolerance. A transcriptional analysis shows that the mutated rpoB gene plays a role in regulating the expression of the SAM-dependent methyltransferase (trm) and transcriptional regulators, to confer moderate tigecycline resistance. This study provides direct in vitro evidence that mutations in the adeS, rpoB and rrf are associated with tigecycline resistance in A. baumannii.

Entities:  

Keywords:  adeS; multidrug-resistant A. baumannii; rpoB; rrf; tigecycline resistance

Year:  2021        PMID: 34170209     DOI: 10.1080/22221751.2021.1948804

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN: 2222-1751            Impact factor:   7.163


  4 in total

1.  Molecular Mechanisms Driving the In Vivo Development of KPC-71-Mediated Resistance to Ceftazidime-Avibactam during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.

Authors:  Xi Li; Huanhuan Ke; Wenhao Wu; Yuexing Tu; Hua Zhou; Yunsong Yu
Journal:  mSphere       Date:  2021-12-22       Impact factor: 4.389

2.  Molecular characterisation of Acinetobacter baumannii isolates from bloodstream infections in a tertiary-level hospital in South Africa.

Authors:  Michelle Lowe; Ashika Singh-Moodley; Husna Ismail; Teena Thomas; Vindana Chibabhai; Trusha Nana; Warren Lowman; Arshad Ismail; Wai Yin Chan; Olga Perovic
Journal:  Front Microbiol       Date:  2022-08-05       Impact factor: 6.064

3.  Co-evolutionary adaptations of Acinetobacter baumannii and a clinical carbapenemase-encoding plasmid during carbapenem exposure.

Authors:  Linyue Zhang; Ying Fu; Linghong Zhang; Qingye Xu; Yunxing Yang; Jintao He; Sebastian Leptihn; Belinda Loh; Robert A Moran; Willem van Schaik; Mark Alexander Toleman; Qiong Chen; Lilin Liu; Yunsong Yu; Xiaoting Hua
Journal:  Evol Appl       Date:  2022-07-05       Impact factor: 4.929

Review 4.  Dissemination and prevalence of plasmid-mediated high-level tigecycline resistance gene tet (X4).

Authors:  Shaqiu Zhang; Jinfeng Wen; Yuwei Wang; Mingshu Wang; Renyong Jia; Shun Chen; Mafeng Liu; Dekang Zhu; Xinxin Zhao; Ying Wu; Qiao Yang; Juan Huang; Xumin Ou; Sai Mao; Qun Gao; Di Sun; Bin Tian; Anchun Cheng
Journal:  Front Microbiol       Date:  2022-09-29       Impact factor: 6.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.